NCT01061606 · OUTCOME

Tumor Response Rate, in Terms of the Proportion of Confirmed Tumor Responses (CR or PR) Assessed Using RECIST

Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus · Source last updated 2016-11-09

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: participants
Interval / dispersion: Not reported
Time frame: Up to 3 years

Groups in this outcome

Treatment (Temsirolimus)

Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. temsirolimus: Given IV

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Treatment (Temsirolimus)	6

Reported measurements

Disease progression

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment (Temsirolimus)	4	Not reported	Not reported	Not reported	Not reported

Stable disease

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment (Temsirolimus)	2	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
4
title
Disease progression
categories
measurements
group Id
OG000
value
2
title
Stable disease

denoms

counts
group Id
OG000
value
6
units
Participants

groups

description
Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. temsirolimus: Given IV
id
OG000
title
Treatment (Temsirolimus)

param Type

NUMBER

reporting Status

POSTED

time Frame

Up to 3 years

title

Tumor Response Rate, in Terms of the Proportion of Confirmed Tumor Responses (CR or PR) Assessed Using RECIST

type

PRIMARY

unit Of Measure

participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice